[go: up one dir, main page]

CL2017001572A1 - Compuestos de triazolopirimidina y usos de los mismos. - Google Patents

Compuestos de triazolopirimidina y usos de los mismos.

Info

Publication number
CL2017001572A1
CL2017001572A1 CL2017001572A CL2017001572A CL2017001572A1 CL 2017001572 A1 CL2017001572 A1 CL 2017001572A1 CL 2017001572 A CL2017001572 A CL 2017001572A CL 2017001572 A CL2017001572 A CL 2017001572A CL 2017001572 A1 CL2017001572 A1 CL 2017001572A1
Authority
CL
Chile
Prior art keywords
triazolopyrimidine compounds
triazolopyrimidine
compounds
mediaated
prc2
Prior art date
Application number
CL2017001572A
Other languages
English (en)
Inventor
Sendzik Martin
Man Chan Ho
Ju Justin Gu Xiang
Huang Ying
Li Ling
Qi Wei
Wang Long
Yu Zhengtian
Zhang Hailong
Yue Jeff Zhang Ji
Zhang Man
Zhang Qiong
Zhao Kehao
Sun Yongfeng
Mi Yuan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2017001572A1 publication Critical patent/CL2017001572A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>SE PROPORCIONA UN COMPUESTO DE LA FORMULA (I), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, EL CUAL SE HA MOSTRADO ES ÚTIL PARA TRATAR UNA ENFERMEDAD O TRASTORNO MEDIADO POR PRC2, EN DONDE R1, R2, R3, R4, R5, Y N SON COMO SE DEFINEN EN LA PRESENTE.</p>
CL2017001572A 2014-12-23 2017-06-16 Compuestos de triazolopirimidina y usos de los mismos. CL2017001572A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23

Publications (1)

Publication Number Publication Date
CL2017001572A1 true CL2017001572A1 (es) 2018-01-12

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001572A CL2017001572A1 (es) 2014-12-23 2017-06-16 Compuestos de triazolopirimidina y usos de los mismos.

Country Status (40)

Country Link
US (5) US9580437B2 (es)
EP (1) EP3237418B1 (es)
JP (1) JP6736559B2 (es)
KR (1) KR102534028B1 (es)
CN (1) CN107108637B (es)
AU (1) AU2015370524B2 (es)
BR (1) BR112017010354B8 (es)
CA (1) CA2969090C (es)
CL (1) CL2017001572A1 (es)
CO (1) CO2017005992A2 (es)
CR (1) CR20170285A (es)
CY (1) CY1121901T1 (es)
DK (1) DK3237418T3 (es)
DO (1) DOP2017000149A (es)
EA (1) EA032416B1 (es)
EC (1) ECSP17047153A (es)
ES (1) ES2722048T3 (es)
GT (1) GT201700146A (es)
HR (1) HRP20190805T1 (es)
HU (1) HUE043060T2 (es)
IL (1) IL252135B (es)
JO (1) JO3489B1 (es)
LT (1) LT3237418T (es)
ME (1) ME03385B (es)
MX (1) MX375970B (es)
MY (1) MY186837A (es)
NZ (1) NZ731664A (es)
PE (1) PE20171307A1 (es)
PH (1) PH12017501016B1 (es)
PL (1) PL3237418T3 (es)
PT (1) PT3237418T (es)
RS (1) RS58679B1 (es)
SG (1) SG11201703880VA (es)
SI (1) SI3237418T1 (es)
SV (1) SV2017005472A (es)
TN (1) TN2017000204A1 (es)
TW (1) TWI694076B (es)
UA (1) UA120945C2 (es)
UY (1) UY36462A (es)
WO (1) WO2016103155A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03385B (me) * 2014-12-23 2020-01-20 Novartis Ag Triazolopirimidin jedinjenja i njihova upotreba
EP3464643A4 (en) 2016-06-01 2020-04-01 Epizyme Inc USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
KR102519922B1 (ko) * 2016-06-20 2023-04-11 노파르티스 아게 트리아졸로피리미딘 화합물의 결정질 형태
CN109906224B (zh) * 2016-06-20 2022-02-25 诺华股份有限公司 三唑吡啶化合物及其应用
EP3472166A1 (en) * 2016-06-20 2019-04-24 Novartis AG Imidazopyrimidine compounds useful for the treatment of cancer
PH12019500056B1 (en) 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
AU2018210770B2 (en) 2017-01-23 2022-03-24 Revolution Medicines, Inc. Bicyclic compounds as allosteric SHP2 inhibitors
MX2019008696A (es) 2017-01-23 2019-09-13 Revolution Medicines Inc Compuestos de piridina como inhibidores de shp2 alostericos.
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
MX393395B (es) * 2017-03-16 2025-03-24 Jiangsu Hengrui Medicine Co Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo.
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
BR112020009757A2 (pt) * 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
US11591312B2 (en) 2018-01-23 2023-02-28 Basf Se Halogenation of pyridine derivatives
EP4043466B1 (en) 2018-01-31 2024-08-21 Mirati Therapeutics, Inc. Prc2 inhibitors
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
WO2020108590A1 (zh) * 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
TWI845638B (zh) 2019-03-15 2024-06-21 美商弗爾康醫療公司 Ｅｅｄ及ｐｒｃ２調節劑之巨環唑并吡啶衍生物
US12351583B2 (en) 2019-04-03 2025-07-08 Chemiteras, Inc. Triazolopyrimidines based on thymine nucleobase and methods for producing them
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN113874377A (zh) 2019-05-13 2021-12-31 埃科莱布美国股份有限公司 作为铜腐蚀抑制剂的1,2,4-三唑并[1,5-a]嘧啶衍生物
JP2022535267A (ja) * 2019-06-05 2022-08-05 アセネックス インコーポレイテッド 乾癬を治療および／または予防する方法
EP3980422A1 (en) * 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
EP3999510A1 (en) 2019-07-16 2022-05-25 The Regents Of The University Of Michigan Imidazopyrimidines as eed inhibitors and the use thereof
WO2021032004A1 (zh) 2019-08-22 2021-02-25 上海青煜医药科技有限公司 氮杂芳基化合物及其应用
CA3150284A1 (en) * 2019-09-26 2021-04-01 Novartis Ag Aza-quinoline compounds and uses thereof
KR102818791B1 (ko) * 2019-11-01 2025-06-11 상하이테크 유니버시티 Eed 억제제, 및 이의 제조방법 및 용도
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
WO2021228034A1 (en) * 2020-05-11 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Preparation method of (5-fluoro-2, 3-dihydrobenzofuran-4-yl) methanamine or its salt, and intermediates thereof
CN115916209A (zh) * 2020-05-28 2023-04-04 诺华股份有限公司 用于治疗PRC2介导的疾病或障碍的N-((5-氟-2,3-二氢苯并呋喃-4-基)甲基)-8-(2-甲基吡啶-3-基)-[1,2,4]三唑并[4,3-c]嘧啶-5-胺或其药学上可接受的盐的给药方案
CN114907385A (zh) * 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
WO2023016511A1 (zh) * 2021-08-11 2023-02-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
WO2024215699A1 (en) * 2023-04-11 2024-10-17 Oric Pharmaceuticals, Inc. Treatment of t-cell lymphoma

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
SE519662C2 (sv) * 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
AU2002357667A1 (en) * 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
BRPI0308113B8 (pt) 2002-03-08 2021-05-25 Eisai Co Ltd compostos macrocíclicos úteis como substâncias farmacêuticas
PA8569301A1 (es) 2002-03-13 2004-10-08 Array Biopharma Inc "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimidazole derivatives as mek inhibitors"
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) * 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP2003196A3 (en) 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
EP1765994B1 (en) 2004-06-01 2009-11-18 The University of North Carolina at Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
PT1912636E (pt) 2005-07-21 2014-07-24 Ardea Biosciences Inc Inibidores de n-(arilamino)-sulfonamida de mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CA2648021A1 (en) 2006-03-31 2007-10-11 Ordway Research Institute, Inc. Prognostic and diagnostic method for cancer therapy
WO2008083251A2 (en) 2006-12-27 2008-07-10 Usc Stevens - University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
EP2426108B1 (en) 2007-08-29 2016-08-10 MethylGene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
KR101584823B1 (ko) 2007-09-12 2016-01-22 제넨테크, 인크. 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
WO2010111712A2 (en) 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
NZ603454A (en) * 2010-05-07 2014-06-27 Glaxosmithkline Llc Indoles useful for treating cellular proliferation diseases such as cancer
KR102511807B1 (ko) 2010-09-10 2023-03-20 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
WO2013010181A2 (en) 2011-07-14 2013-01-17 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
BR112014007603A2 (pt) 2011-09-30 2017-06-13 Glaxosmithkline Llc métodos de tratamento do câncer
EP2825161B1 (en) 2012-03-12 2019-01-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
CN105189506A (zh) 2012-11-19 2015-12-23 诺华股份有限公司 用于治疗寄生虫疾病的化合物和组合物
US20150313906A1 (en) 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
EP2954056A4 (en) 2013-02-08 2016-09-21 Stemcentrx Inc NEW MULTISPECIFIC CONSTRUCTIONS
RS56207B1 (sr) 2013-02-11 2017-11-30 Constellation Pharmaceuticals Inc Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba
WO2014153030A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2939219C (en) 2014-02-11 2023-02-28 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
WO2016075289A1 (en) 2014-11-14 2016-05-19 Basf Se Benzylpropargylether as nitrification inhibitors
PT3033944T (pt) 2014-12-16 2018-05-14 Omya Int Ag Carbonato de cálcio para proteção de plantas
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
ME03385B (me) * 2014-12-23 2020-01-20 Novartis Ag Triazolopirimidin jedinjenja i njihova upotreba

Also Published As

Publication number Publication date
CR20170285A (es) 2017-08-21
MX2017008529A (es) 2017-10-25
NZ731664A (en) 2024-02-23
JP6736559B2 (ja) 2020-08-05
CY1121901T1 (el) 2020-10-14
PT3237418T (pt) 2019-05-23
US11207325B2 (en) 2021-12-28
PH12017501016A1 (en) 2017-12-11
ME03385B (me) 2020-01-20
UY36462A (es) 2016-07-29
JP2018500342A (ja) 2018-01-11
JO3489B1 (ar) 2020-07-05
AU2015370524A1 (en) 2017-06-01
EA201791420A1 (ru) 2017-10-31
UA120945C2 (uk) 2020-03-10
CN107108637B (zh) 2019-10-29
ES2722048T3 (es) 2019-08-07
BR112017010354B8 (pt) 2022-10-18
WO2016103155A1 (en) 2016-06-30
SG11201703880VA (en) 2017-07-28
US11931363B2 (en) 2024-03-19
IL252135A0 (en) 2017-07-31
ECSP17047153A (es) 2019-02-28
PL3237418T3 (pl) 2019-07-31
MX375970B (es) 2025-03-06
DK3237418T3 (da) 2019-05-13
TW201629065A (zh) 2016-08-16
LT3237418T (lt) 2019-05-10
AU2015370524B2 (en) 2018-11-01
CA2969090A1 (en) 2016-06-30
DOP2017000149A (es) 2017-07-15
TWI694076B (zh) 2020-05-21
US20190142837A1 (en) 2019-05-16
KR102534028B1 (ko) 2023-05-19
IL252135B (en) 2020-06-30
EP3237418B1 (en) 2019-01-30
US20200323859A1 (en) 2020-10-15
US9580437B2 (en) 2017-02-28
RS58679B1 (sr) 2019-06-28
GT201700146A (es) 2019-06-12
SI3237418T1 (sl) 2019-06-28
US20160176882A1 (en) 2016-06-23
EA032416B1 (ru) 2019-05-31
KR20170095882A (ko) 2017-08-23
BR112017010354A2 (pt) 2017-12-26
PH12017501016B1 (en) 2017-12-11
SV2017005472A (es) 2018-06-12
HRP20190805T1 (hr) 2019-06-28
US10220036B2 (en) 2019-03-05
EP3237418A1 (en) 2017-11-01
HUE043060T2 (hu) 2019-07-29
MY186837A (en) 2021-08-25
CN107108637A (zh) 2017-08-29
US20230033320A1 (en) 2023-02-02
US20170348312A1 (en) 2017-12-07
PE20171307A1 (es) 2017-09-05
BR112017010354B1 (pt) 2022-09-20
CO2017005992A2 (es) 2017-10-20
CA2969090C (en) 2023-05-02
TN2017000204A1 (en) 2018-10-19

Similar Documents

Publication Publication Date Title
CL2017001572A1 (es) Compuestos de triazolopirimidina y usos de los mismos.
CO2017001884A2 (es) Polimorfos de selinexor
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
CL2017000310A1 (es) Anticuerpos anti tigit
CL2016003293A1 (es) Inhibidores de mnk y método relacionado al mismo
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
ECSP17007336A (es) Compuestos de imidazopiridazina
CU24392B1 (es) Compuestos y composiciones para inducir condrogénesis
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
CL2019000487A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana.
CR20150641U (es) Composiciones farmacéuticas
AR120118A2 (es) Anticuerpos anti tigit
CO2017003225A2 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos
GT201500232A (es) Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis
UY36284A (es) Método para la preparación de imidazopiridazinas sustituidas